Portal de Yecla

Yecla - SpanishYecla - English
detail of Yecla


[The patented product, BioGraph, has unique characteristics in dermatological treatments such as wound healing time (17/12/2020)

| Studies are being carried out on its virucidal capacity against SARS-COV-2 and its possible use in sanitary applications, protective material and PPE, with encouraging results | Graphenano Group, the first global firm to introduce graphene in dermatological and cosmetic treatments The Spanish company Graphenano Medical Care has managed to become the first global firm to introduce graphene in different fields of medicine and cosmetics.

The firm, founded in the Murcian town of Yecla, has achieved a milestone in the field of nanotechnology by patenting BioGraph, a derivative of graphene capable, among other applications, of considerably reducing wound healing time.

Four years of development carried out by a research group from Graphenano Medical Care, which works at the University of Alcal and is led by Professors Manuel and Diego Rodríguez Puyol, have achieved that graphene can begin to used in medical and dermatological treatments thanks to its unique characteristics.

This development has been fully financed by the Graphenano Group, a world reference in the graphene and nanotechnology sector, and which has several subsidiaries in fields as diverse as construction, composites, dentistry and energy, with products already positioned in the market.

Graphenano Medical Care was founded in 2016 and its mission is to develop biomedical and cosmetic applications based on the exceptional properties of graphene and its derivatives.

Certified by AENOR as a Young Innovative Company, JEI-2020/0009, it is a subsidiary of Graphenano Nanotechnologies.

One of his lines of research, "Synthesis of graphene derivatives and their application in the biomedical and cosmetic field", is also certified by AENOR, PIDI-0156 / 2020.

A milestone for Graphenano Medical Care in the field of nanotechnology has been to patent a derivative of graphene called BioGraph, highly biocompatible and safe, lacking genotoxicity and mutagenicity, according to tests carried out by certified external laboratories.

BioGraph is inscribed on the list of "International Nomenclatures of Cosmetic Ingredients (INCI)" and has proven to be very effective in different fields of cosmetics.

As a consequence, the presentation on the market of a line of products developed in collaboration with Global Biotech SL is imminent, combining the revolutionary properties of BioGraph with those of Porphyridium Polysaccharide extract.

On the other hand, always using BioGraph as a starting element, Graphenano Medical Care has developed a skin healing agent, BioGraph-Skin, capable of considerably reducing wound healing time.

Different procedures are in place to develop its use in humans and obtain the pertinent permits.

Taking into account the bacteriostatic properties of BioGraph and its protective effect against certain viruses, in the context of the emergency caused by the COVID-19 pandemic, studies are being carried out on the virucidal capacity of these products against SARS-COV- 2 and its possible use in sanitary applications, protective material and PPE, with encouraging results that will be announced shortly.

Graphenano was founded in Yecla by the brothers Mart ny Jos Antonio Mart nez together with the German investor George Escoda in early 2012 and they began to manufacture Graphene in the first plant in Ciudad Real.

They invested their heritage in research of applications with graphene in different universities in Spain.

At present they have different divisions each in charge of very different sectors such as construction materials, composites, medicine, dental, additives, sensors and energy.

function { ;(, , {});}

Source: Agencias

UNE-EN ISO 9001:2000 - ER-0131/2006 © 2021 Alamo Networks S.L. - C/Alamo 8, 30850 Totana (Murcia) Privacy policy - Legal notice Región de Murcia
Este sitio web utiliza cookies para facilitar y mejorar la navegación. Si continúas navegando, consideramos que aceptas su uso. Más información